1. Home
  2. BIRK vs PCVX Comparison

BIRK vs PCVX Comparison

Compare BIRK & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Birkenstock Holding plc

BIRK

Birkenstock Holding plc

HOLD

Current Price

$43.89

Market Cap

8.5B

Sector

N/A

ML Signal

HOLD

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

HOLD

Current Price

$56.64

Market Cap

7.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIRK
PCVX
Founded
1774
2013
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
7.0B
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
BIRK
PCVX
Price
$43.89
$56.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
4
Target Price
$61.43
$88.25
AVG Volume (30 Days)
1.8M
1.5M
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.71
N/A
Revenue Next Year
$14.30
N/A
P/E Ratio
$17.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$31.33
$29.10
52 Week High
$53.53
$65.00

Technical Indicators

Market Signals
Indicator
BIRK
PCVX
Relative Strength Index (RSI) 49.64 54.14
Support Level $40.98 $52.04
Resistance Level $45.22 $63.36
Average True Range (ATR) 1.96 2.51
MACD -0.30 -0.27
Stochastic Oscillator 47.65 28.41

Price Performance

Historical Comparison
BIRK
PCVX

About BIRK Birkenstock Holding plc

Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: